| Literature DB >> 25349607 |
Christopher A Shaw1, Stephanie Seneff2, Stephen D Kette3, Lucija Tomljenovic4, John W Oller5, Robert M Davidson6.
Abstract
Over the last 200 years, mining, smelting, and refining of aluminum (Al) in various forms have increasingly exposed living species to this naturally abundant metal. Because of its prevalence in the earth's crust, prior to its recent uses it was regarded as inert and therefore harmless. However, Al is invariably toxic to living systems and has no known beneficial role in any biological systems. Humans are increasingly exposed to Al from food, water, medicinals, vaccines, and cosmetics, as well as from industrial occupational exposure. Al disrupts biological self-ordering, energy transduction, and signaling systems, thus increasing biosemiotic entropy. Beginning with the biophysics of water, disruption progresses through the macromolecules that are crucial to living processes (DNAs, RNAs, proteoglycans, and proteins). It injures cells, circuits, and subsystems and can cause catastrophic failures ending in death. Al forms toxic complexes with other elements, such as fluorine, and interacts negatively with mercury, lead, and glyphosate. Al negatively impacts the central nervous system in all species that have been studied, including humans. Because of the global impacts of Al on water dynamics and biosemiotic systems, CNS disorders in humans are sensitive indicators of the Al toxicants to which we are being exposed.Entities:
Year: 2014 PMID: 25349607 PMCID: PMC4202242 DOI: 10.1155/2014/491316
Source DB: PubMed Journal: J Toxicol ISSN: 1687-8191
Common sources of Al compounds and their immunoneurotoxicological effects in humans and animals.
| Aluminum source/compound | Dose & duration | Route | Species | Adverse effects |
|---|---|---|---|---|
| Standard infant feeding solution | ~20 | Intravenous (parenteral) | Human, premature infants | Reduced developmental attainment at the corrected post-term age of 18 months, as evidenced by significantly lower Bayley Mental Development Index (BMDI) scores (mean loss of one point on the BMDI/day of full intravenous feeding, after adjustment for potentially confounding factors) compared to infants fed with Al-depleted solutions [ |
|
| ||||
| Al-containing dialysis fluid (derived from Al-sulfate treated tap water) | 1 ppm, chronic | Intravenous | Human, dialysis patients (15–61 years old at the start of the dialysis treatment) | Speech impairments (stuttering, dysarthria, dyspraxia, and motor aphasia), movement disorders (twitches, tremors, myoclonic jerks, seizures, and motor apraxia), cognitive impairments and behavioural changes (progressive dementia, paranoia, confusion, and psychosis), and death [ |
|
| ||||
| Al-containing antacids | Chronic | Oral | Human infants | Craniosynostosis (premature ossification of the skull and obliteration of the sutures) [ |
|
| ||||
| Various dietary | Chronic | Oral | Elderly human subjects | Impaired visuomotor coordination, poor long-term memory, and increased sensitivity to flicker (correlated with high Al-serum levels) [ |
|
| ||||
| Al sulfate | 500–3000 x the acceptable limit under European Union Legislation (0.200 mg/L), chronic (15 years) | Oral | Human adult (female, 44 years old) | Sporadic early-onset |
|
| ||||
| Al-containing food pellets | 0.5–1.7 mg/kg/day (typical human), chronic (22–32 months) | Oral | Rats, 6 months old at the start of treatment | Cognitive deterioration and impaired performance in learning tasks, impaired concentration, and behavioral changes including confusion and repetitive behaviour [ |
|
| ||||
| Al lactate | 500–1000 ppm, chronic (during gestation and lactation) | Oral | Mice dams | Hind limb paralysis, seizures, and death (dams), lower neurobehavioral development and altered performance on a neurobehavioral test battery in pups (foot splay, forelimb, and hind limb grip strengths reduced) [ |
|
| ||||
| Al hydroxide as a vaccine adjuvant | 1–17 doses of Al-containing vaccines (hepatitis B, hepatitis A, and tetanus toxoid) in the period of 10 years prior to disease diagnosis | Intramuscular injection | Human adult macrophagic myofasciitis (MMF) syndrome patients (mean age 45 years) | MMF typical clinical manifestations: myalgia, arthralgia, chronic fatigue (disabling fatigue >6 months), muscle weakness and cognitive dysfunction (overt cognitive alterations affecting memory, and attention manifested in 51% of cases) [ |
|
| ||||
| Al hydroxide as a vaccine adjuvant | 14 injections over a 6-month period | Subcutaneous | Sheep, male 3 month old lambs | “Sheep adjuvant syndrome” first identified following mass-vaccination for bluetongue; experimentally reproduced by repetitive injection with Al-containing vaccines [ |
|
| ||||
| Al hydroxide as a vaccine adjuvant | 2 injections, | Subcutaneous injection (behind the neck) | Mice, 3 months old CD-1 male | Motor neuron degeneration and apoptosis, motor function deficits, decrease in strength, cognitive deficits, and decreased performance in learning tasks, decrements in spatial memory, activation of microglia [ |
|
| ||||
| Al oxide fumes, occupational exposure | 0.13–1.95 mg/m3, chronic | Inhalation | Human, adults | Headache, emotional irritability, concentration difficulty, insomnia, mood lability [ |
Estimates of daily and weekly intakes of Al in humans [28, 74].
| Major sources of Al exposure in humans | Daily Al intake (mg/day) | Weekly Al intake (mg/day) | ÷PTWI† (1 mg/kg/bw; for an average 70 kg human PTWI = 70 mg) | Amount delivered daily into systemic circulation (at 0.25% absorption rate) |
|---|---|---|---|---|
| Natural food | 1–10 [ | 7–70 | 0.1–1 | 2.5–25 |
| Food with Al additives | 1–20 (individual intake can exceed 100) [ | 7–140 | 0.1–2 | 2.5–50 |
| Water | 0.08–0.224 [ | 0.56–1.56 | 0.008–0.02 | 0.2–0.56 |
| Pharmaceuticals (antacids, buffered analgesics, antiulceratives, and antidiarrheal drugs) | 126–5000 [ | 882–35,000 | 12.6–500 | 315–12,500 |
| Vaccines (HepB, Hib, Td, DTP) | 0.51–4.56 [ | NA | NA | 510-4560 |
| Cosmetics, skin-care products, and antiperspirants§ | 70 [ | 490 | NA | 8.4 |
| Cooking utensils and food packaging | 0–2 [ | 0–14 | 0–0.2 | 0–5 |
†PTWI (provisional tolerable weekly intake) is based on orally ingested Al, generally only 0.1–0.4% of Al is absorbed from the GI tract, however, Al may form complexes with citrate, fluoride, carbohydrates, phosphates, and dietary acids (malic, oxalic, tartaric, succinic, aspartic, and glutamic), which may increase its GI absorption (0.5–5% [70, 82]). Coexposure to acidic beverages (lemon juice, tomato juice, and coffee) also increases Al absorption as well as conditions of Ca2+, Mg2+, Cu2+, and Zn2+ deficiency [70, 83–85].
‡A single dose of vaccine delivers the equivalent of 204–1284 mg orally ingested Al (0.51−5.56 mg), all of which is absorbed into systemic circulation [86, 91]. Al hydroxide, a common vaccine adjuvant has been linked to a host of neurodegenerative diseases; it also induces hyperphosphorylation of MAP tau in vivo [44, 45, 87].
§The risk of antiperspirants is both from dermal exposure and inhalation of acrosols. Al is absorbed from the nasal epithelia into olfactory nerves and distributed directly into the brain [88, 91].
A comparison of the physical properties of metallic Al with those of its common competitors in biological systems [89]. Crystal ionic radius source: [92]. Magnetic susceptibilities source: [47, pp. 4-131 to 4-136]. Viscosity B coefficient source: [93]. Standard molar electrostriction volume source [94].
| Mg | Al | Ca | Mn | Fe | Co | Zn | |
|---|---|---|---|---|---|---|---|
| Atomic number | 12 | 13 | 20 | 24 | 25 | 27 | 30 |
| Electron configuration | [Ne]3s2 | [Ne]3s23p1 | [Ar]4s2 | [Ar]4s23d5 | [Ar]4s23d6 | [Ar]4s23d7 | [Ar]4s23d10 |
| Ionization energies (kJ/mol) | 737.7 | 577.5 | 589.8 | 717.3 | 762.6 | 760.4 | 906.4 |
| Crystal ionic radius (pm) | 86 | 67.5 | 114 | 97 | 92 | 135 | 88 |
| Electron affinity (kJ/mol) | 0 | 42.5 | 2.37 | 0 | 15.7 | 63.7 | 0 |
| Electronegativity (eV) | 1.31 | 1.61 | 1.0 | 1.55 | 1.83 | 1.88 | 1.65 |
| Magnetic susceptibility | +13.1 | +16.5 | +40 | +511 |
|
| −9.15 |
| Charge density (coulombs | 120.1 | 372.6 | 51.6 | 143.7 | 98.1 | 154.9 | 112.1 |
| Viscosity | 0.385 | 0.75 | 0.289 | 0.390 | 0.42 | 0.376 | 0.361 |
| Standard molar electrostriction volume (−Δelstr
| 52.5 | 59.3 | 38.5 | 30.7 | — | 38.5 | — |
Summary comparisons of chaotropic versus kosmotropic ions.
| Chaotropes (water-structure breakers) | Kosmotropes (water-structure makers) |
|---|---|
| Typically larger radius, singly charged ions with low charge density | Typically small radius, often multiply charged ions with high charge density |
| Interact more weakly with waters than water molecules interact with each other | Interact more strongly with waters than water molecules interact with each other |
| Interfere little with hydrogen bonds of the surrounding waters | Capable of weakening and breaking hydrogen bonds of the surrounding waters |
| Decrease surface tension | Increase surface tension |
| Reduce viscosity | Increase viscosity |
| Increase nonpolar solubility | Decrease nonpolar solubility |
| Unfold proteins | Stabilize proteins |
| Destabilize hydrophobic aggregates | Stabilize hydrophobic aggregates and bonding |
| Increase solubility of hydrophobic solutes | Reduce solubility of hydrophobic solutes |
| Salt in proteins | Salt out proteins |
| Net positive entropy of ion solvation | Net negative entropy of ion solvation |
Figure 2Depiction of how Gadolinium (Gd3+) vibronic side band luminescence spectroscopy (GVSBLS) acts as a probe of the coordination of biologically-relevant sites of cation sequestration. The figure is reproduced here from (Guo and Friedman 2009) [139] with permission of the American Chemical Society. Copyright 2009 American Chemical Society.
Figure 1Semirigid hydration and cooperativity ((a) and (b)) a water molecule in the solvation shell of a cation (a) and an anion (b). Dielectric relaxation measurements probe the reorientation of the permanent dipole vector p. Femtosecond infrared spectroscopy is sensitive to the reorientation of the OD-stretch transition dipole moment . The dotted arrows indicate reorientation in a cone, in the case of semirigid hydration. (c) Proposed geometry, in which the water dynamics are locked in two directions because of the cooperative interaction with the cation and the anion. Figure 1 is reproduced here from (Tielrooij et al. 2010) [153] with permission of the American Association for the Advancement of Science.
Selected hydration enthalpies of common biologically relevant ions [89].
| Symbol | Δ | Source |
|---|---|---|
| NO3 − | −312 | [ |
| K+ | −321 | [ |
| NH4 + | −329 | [ |
| HSO4 − | −368 | [ |
| Cl− | −371 | [ |
| HCO3 − | −384 | [ |
| Na+ | −413 | [ |
| OH− | −520 | [ |
| H2PO4 − | −522 | [ |
| SO4 2− | −1035 | [ |
| H+ | −1100 | [ |
| Ca2+ | −1650 | [ |
| Mg2+ | −1920 | [ |
| Mg2+ | −1949 | [ |
| Al3+ | −4690 | [ |
Three different formulations of the DTaP vaccine and the number of reported adverse reactions available from VAERS for each one.
| Formulation | Adjuvant | Adverse reactions |
|---|---|---|
| Tripedia | Aluminum potassium sulfate | 11,178 |
| Daptacel | Aluminum phosphate | 8,786 |
| Infanrix | Aluminum hydroxide | 13,238 |
Adverse reactions reported in VAERS for sulfate versus hydroxide in age-matched samples, and the likelihood that the contrasts observed in these distributions could have occurred by chance (p < 0.05).
| Condition | Sulfate | Hydroxide |
|
|---|---|---|---|
| Swelling | 2210 | 2665 | 0.0066 |
| Cellulitis | 445 | 617 | 0.020 |
| Pain | 622 | 815 | 0.020 |
| Fever | 2032 | 2296 | 0.034 |
| Injection site reaction | 393 | 520 | 0.038 |
| Injection site swelling | 7 | 33 | 0.045 |
Counts of various adverse reactions reported in VAERS for sulfate versus phosphate in age-matched equal subsets of the sample space, and the likelihood that the contrasts observed in these distributions could have occurred by chance according to a log likelihood ratio test. Included are all the reactions for which phosphate was more common with a p value under 0.05.
| Condition | Sulfate | Phosphate |
|
|---|---|---|---|
| Hospitalization | 177 | 363 | 0.0044 |
| Seizures | 186 | 333 | 0.011 |
| Rotavirus | 3 | 47 | 0.013 |
| Abdominal pain | 6 | 53 | 0.014 |
| Nausea | 203 | 338 | 0.015 |
| Diarrhea | 95 | 174 | 0.028 |
| Pneumonia | 13 | 50 | 0.032 |
| Dehydration | 12 | 48 | 0.032 |
| Throat irritation | 81 | 147 | 0.036 |
Figure 3Illustration of the devastating effects of Aluminum on a typical cell related to sulfate inactivation, G-protein signaling, and calmodulin signaling. (a) A healthy cell without Al contamination. eNOS, attached to the membrane at a caveola, produces sulfate, which maintains a healthy glycocalyx with sufficient negative charge. (b) Al binds to the sulfates, eliminating the negative charge, which allows cytokines to penetrate through the glycocalyx, activating G-protein coupled receptor signaling cascades. AlF4 − disrupts the signal, acting as a phosphate mimic, and Al binds to CaM, inducing eNOS detachment from the membrane. Phosphorylation cascades activate eNOS to produce abundant NO released into the cytoplasm, instead of producing sulfate to enrich the glycocalyx.
Figure 4Schematic of the biosemiotic levels at which Al can impact the body and CNS.